Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fluorouracil + Leucovorin + Oxaliplatin + SAR445877 |
| Synonyms | SAR445877 + FOLFOX6 |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent that interferes with DNA and RNA synthesis, thereby preventing cancer cell growth (PMID: 28520376). Adrucil (fluorouracil) is FDA-approved for use in patients with adenocarcinoma of the colon, rectum, breast, stomach, and pancreas (FDA.gov). |
| Leucovorin | Wellcovorin | Calcium folinate|Calcium citrovorum factor|folinic acid | Chemotherapy - Antimetabolite 14 | Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554). |
| Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
| SAR445877 | SAR 445877|SAR-445877|KD 050|KD-050|KD050|mut-1N-IL-15/38B2 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 137 | SAR445877 is an antibody cytokine fusion molecule comprising an anti-PD-1 (PDCD1) antibody linked to a mutated fusion of human IL15 and human IL15 receptor-alpha sushi domain, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2972). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07500298 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + SAR445877 Fluorouracil + Leucovorin + Oxaliplatin + SAR445877 | Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer | Not yet recruiting | USA | 0 |